• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

无定形固体分散体中共存的卤键和氢键对药物溶解度、混溶性和迁移性的影响。

Implications of Coexistent Halogen and Hydrogen Bonds in Amorphous Solid Dispersions on Drug Solubility, Miscibility, and Mobility.

机构信息

School of Pharmacy and Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Ave, Pittsburgh, Pennsylvania 15282, United States.

出版信息

Mol Pharm. 2022 Nov 7;19(11):3959-3972. doi: 10.1021/acs.molpharmaceut.2c00434. Epub 2022 Sep 1.

DOI:10.1021/acs.molpharmaceut.2c00434
PMID:36049226
Abstract

Specific noncovalent drug-polymer interactions were analytically identified using Raman and Fourier transform infrared spectroscopy for amorphous solid dispersions (ASD) formed between either chlorpropamide or tolbutamide and polyvinylpyrrolidone vinyl acetate random copolymer (PVPVA). Spectral changes in the C-Cl stretching vibrations due to changes in the electronic environment of the Cl atom confirmed halogen bond formation in chlorpropamide-PVPVA ASDs, the extent of which was established to be inversely related to the concentration of the drug using 2D correlation spectroscopy analysis. Hydrogen bonding between the secondary amide of each drug and the pyrrolidone carbonyl of the copolymer was also confirmed in all dispersions. Implications of coexistent interactions were investigated for drug-polymer solubility, mixing free energy, and molecular mobility relative to tolbutamide, which only formed hydrogen bonds with PVPVA. Chlorpropamide had a higher solubility, a larger negative mixing free energy, and lower mobility in PVPVA relative to tolbutamide. These thermodynamic and kinetic differences demonstrate the significance of halogen bond formation even when hydrogen bonding is present.

摘要

使用拉曼和傅里叶变换红外光谱分析鉴定了氯丙酰胺或甲苯磺丁脲与聚乙烯吡咯烷酮醋酸乙烯酯无规共聚物(PVPVA)形成的无定形固体分散体(ASD)中特定的非共价药物-聚合物相互作用。由于 Cl 原子的电子环境发生变化,C-Cl 伸缩振动的光谱发生变化,证实了氯丙酰胺-PVPVA ASD 中形成了卤键,其程度通过二维相关光谱分析确定与药物浓度成反比。在所有分散体中,还确认了每个药物的仲酰胺与共聚物的吡咯烷酮羰基之间的氢键。共存相互作用的影响对于药物-聚合物的溶解度、混合自由能以及相对于仅与 PVPVA 形成氢键的甲苯磺丁脲的分子迁移率进行了研究。与甲苯磺丁脲相比,氯丙酰胺在 PVPVA 中的溶解度更高,混合自由能的负值更大,分子迁移率更低。这些热力学和动力学差异表明,即使存在氢键,卤键的形成也具有重要意义。

相似文献

1
Implications of Coexistent Halogen and Hydrogen Bonds in Amorphous Solid Dispersions on Drug Solubility, Miscibility, and Mobility.无定形固体分散体中共存的卤键和氢键对药物溶解度、混溶性和迁移性的影响。
Mol Pharm. 2022 Nov 7;19(11):3959-3972. doi: 10.1021/acs.molpharmaceut.2c00434. Epub 2022 Sep 1.
2
Congruent Release of Drug and Polymer from Amorphous Solid Dispersions: Insights into the Role of Drug-Polymer Hydrogen Bonding, Surface Crystallization, and Glass Transition.无定形固体分散体中药物和聚合物的一致释放:对药物-聚合物氢键、表面结晶和玻璃化转变作用的深入了解。
Mol Pharm. 2020 Apr 6;17(4):1261-1275. doi: 10.1021/acs.molpharmaceut.9b01272. Epub 2020 Mar 17.
3
Insights into the Dissolution Mechanism of Ritonavir-Copovidone Amorphous Solid Dispersions: Importance of Congruent Release for Enhanced Performance.利托那韦-共聚维酮无定形固体分散体的溶解机制研究:一致释放对于增强性能的重要性。
Mol Pharm. 2019 Mar 4;16(3):1327-1339. doi: 10.1021/acs.molpharmaceut.8b01261. Epub 2019 Feb 5.
4
Impact of Drug-Polymer Intermolecular Interactions on Dissolution Performance of Copovidone-Based Amorphous Solid Dispersions.载药聚合物分子间相互作用对共聚维酮无定形固体分散体溶出性能的影响。
Mol Pharm. 2021 Sep 6;18(9):3496-3508. doi: 10.1021/acs.molpharmaceut.1c00419. Epub 2021 Jul 28.
5
Exploring the influence of hydrogen bond donor groups on the microstructure and intermolecular interactions of amorphous solid dispersions containing diflunisal structural analogues.探索氢键供体基团对含双氯芬酸钠结构类似物无定形固体分散体微观结构和分子间相互作用的影响。
Int J Pharm. 2024 Aug 15;661:124438. doi: 10.1016/j.ijpharm.2024.124438. Epub 2024 Jul 5.
6
Effects of Molecular Interactions on Miscibility and Mobility of Ibuprofen in Amorphous Solid Dispersions With Various Polymers.分子相互作用对不同聚合物无定形固体分散体中布洛芬相容性和迁移性的影响。
J Pharm Sci. 2019 Jan;108(1):178-186. doi: 10.1016/j.xphs.2018.10.052. Epub 2018 Nov 3.
7
Investigation into Intermolecular Interactions and Phase Behavior of Binary and Ternary Amorphous Solid Dispersions of Ketoconazole.酮康唑二元和三元无定形固体分散体的分子间相互作用和相行为研究。
Mol Pharm. 2020 Mar 2;17(3):787-801. doi: 10.1021/acs.molpharmaceut.9b00970. Epub 2020 Feb 20.
8
Miniaturized Measurement of Drug-Polymer Interactions via Viscosity Increase for Polymer Selection in Amorphous Solid Dispersions.通过粘度增加对无定形固体分散体中的聚合物进行选择来进行药物-聚合物相互作用的微型化测量。
Mol Pharm. 2019 May 6;16(5):2214-2225. doi: 10.1021/acs.molpharmaceut.9b00186. Epub 2019 Apr 12.
9
Balancing Solid-State Stability and Dissolution Performance of Lumefantrine Amorphous Solid Dispersions: The Role of Polymer Choice and Drug-Polymer Interactions.平衡稳定性和溶解性能的固态无定形固体分散体:聚合物选择和药物-聚合物相互作用的作用。
Mol Pharm. 2022 Feb 7;19(2):392-413. doi: 10.1021/acs.molpharmaceut.1c00481. Epub 2021 Sep 8.
10
Complementarity of mDSC, DMA, and DRS Techniques in the Study of and Sub- Transitions in Amorphous Solids: PVPVA, Indomethacin, and Amorphous Solid Dispersions Based on Indomethacin/PVPVA.无定形固体中 和 亚转变的研究中 mDSC、DMA 和 DRS 技术的互补性:基于吲哚美辛/PVPVA 的 PVPVA、吲哚美辛和无定形固体分散体。
Mol Pharm. 2022 Jul 4;19(7):2299-2315. doi: 10.1021/acs.molpharmaceut.2c00123. Epub 2022 Jun 8.

引用本文的文献

1
Advances in the development of amorphous solid dispersions: The role of polymeric carriers.非晶态固体分散体的发展进展:聚合物载体的作用。
Asian J Pharm Sci. 2023 Jul;18(4):100834. doi: 10.1016/j.ajps.2023.100834. Epub 2023 Aug 1.
2
The Implications of Drug-Polymer Interactions on the Physical Stability of Amorphous Solid Dispersions.药物-聚合物相互作用对无定形固体分散体物理稳定性的影响。
Pharm Res. 2023 Dec;40(12):2963-2981. doi: 10.1007/s11095-023-03547-4. Epub 2023 Jun 30.
3
Pre-Processing a Polymer Blend into a Polymer Alloy by KinetiSol Enables Increased Ivacaftor Amorphous Solid Dispersion Drug Loading and Dissolution.
通过KinetiSol将聚合物共混物预处理成聚合物合金可提高依伐卡托无定形固体分散体的药物载量和溶出度。
Biomedicines. 2023 Apr 26;11(5):1281. doi: 10.3390/biomedicines11051281.